

**Initial REMS Approval: 06/2014**

**NDA 204399**

**VOGELXO (testosterone) gel CIII  
and Authorized Generic (testosterone gel) CIII**

**Class of Drug: Androgen**

**UPSHER-SMITH LABORATORIES, INC.  
6701 Evenstad Drive  
Maple Grove, MN 55369  
763-315-2000**

**RISK EVALUATION AND MITIGATION STRATEGY (REMS)**

**I. GOAL:**

The goal of this REMS is to inform patients about the serious risks associated with the use of testosterone gel.

**II. REMS ELEMENTS:**

**A. Medication Guide**

A Medication Guide will be dispensed with each testosterone gel prescription in accordance with 21 CFR 208.24.

The Medication Guide is part of the REMS.

**B. Timetable for Submission of Assessments**

Upsher-Smith Laboratories, Inc. (USL) will submit REMS Assessments to the FDA for testosterone gel at 18 months, 3 years and 7 years from the date of initial approval of the VOGELXO (testosterone) gel REMS.

To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 days before the submission date for that assessment. USL will submit each assessment so that it will be received by the FDA on or before the due date.

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

CHRISTINE P NGUYEN  
06/04/2014